Currently approved in multiple countries for psoriasis and PsA treatment, Brodalumab’s receptor-centric targeting strategy demonstrates potential therapeutic value for diseases involving complex interactions among IL-17 subtypes. This evidence concerns the gene IL17A and psoriasis.